Viewing entries posted in 2014
Sequana Medical’s new alfapump® with DirectLink Technology improves the care of patients with challenging refractory ascites
Technological advances in Sequana Medical’s alfapump system will allow patients and their doctors to better manage the distressing symptoms of refractory ascites. With enhanced communications enabled by the new DirectLink Technology, clinicians will now be able to monitor the alfapump remotely.
The Financial Times, one of the world’s leading business news organisations, reported today that Sequana Medical has raised $26 million in a Series C financing round.
Sequana Medical is delighted to be attending this year’s International Liver Congress in London.
Sequana Medical is delighted to report that HUG, the university hospital of Geneva, is now offering the alfapump system as a treatment option for patients suffering from refractory ascites.
The alfapump system featured once again in the British press, this time in the ‘Sun’ newspaper.